Novan Inc

Novan — Investor Presentation (September 2020)

24 slides from Novan's investor presentation, Sep 14, 2020

  1. Slide 1: Nitric Oxide-Based Medicine Corporate Presentation

    novan.com Exhibit 99.2 NASDAQ: NOVN Nitric Oxide-Based Medicine Corporate Presentation September 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates and our intention to advance development of certain product candidates, including the timing,

  3. Slide 3: Ongoing pivotal Phase 3 study with data targeted Q2 2021

    Ongoing pivotal Phase 3 study with data targeted Q2 2021 3

  4. Slide 4: Investment Opportunity

    Investment Opportunity Company’s First Potential NDA Filing Targeted 2022 NITRICIL™ Significant Market Pipeline Expansion Platform Opportunity Opportunities O ~3.4 million1 N Leveraging nitric oxide’s naturally Lead program, SB206 Targeting multiple indications in occurring antiviral and ongoing piv

  5. Slide 5: Priority Development Pipeline

    Priority Development Pipeline Product Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval Program Highlight Candidate DERMATOLOGY Target Reporting Topline SB206 Molluscum Results Q2 2021 INFECTIOUS DISEASE Target Reporting Findings Undisclosed Coronaviridae from in vitro assessments Before Year End

  6. Slide 6: Team With Proven Drug Development Experience

    Team With Proven Drug Development Experience Paula Brown Stafford, MPH Carri Geer, Ph.D. Elizabeth Messersmith, Ph.D. President, CEO, and Chairman SVP and CTO SVP and CDO John M. Gay, CPA Tomoko Maeda-Chubachi, MD, Ph.D., MBA VP, Finance and Corporate Controller VP, Medical Dermatology 6

  7. Slide 7: NITRICIL: Nitric oxide (NO) for therapeutic innovation

    NITRICIL™ Nitric oxide (NO) for therapeutic innovation 7

  8. Slide 8: Nitric Oxide (NO): Naturally Occurring Antiviral and Immunomodulatory Effects

    Nitric Oxide (NO) Naturally Occurring Antiviral and Immunomodulatory Effects O N 8 Colasanti, M. et al. S-Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide IUBMB Life; 1999 (48) 25-31. Kroen, KD. J Clin Invest. 1993;91(6):2446- 2452.; Karupiah, G; et al. Science.

  9. Slide 9: Proprietary Nitric Oxide Based Technology Platform

    ™ Tunable Dosing Enables NITRICIL Proprietary Formulations That Proprietary Nitric Oxide Based Technology Platform Target Each Indication Generates Macromolecular New Chemical Entities (NCEs) Real-Time NO Release 1000 Nitricil 800 600 NVN4428 400 NVN1000 Key Characteristics: 200 Ppb NO/ Ppb mg of 0

  10. Slide 10: SB206: Lead Program

    SB206: Lead Program Ongoing pivotal Phase 3 study for treatment of molluscum 10

  11. Slide 11: SB206: Berdazimer Sodium Topical Antiviral Gel for Viral Skin Infections

    SB206: Berdazimer Sodium Topical Antiviral Gel for the Treatment Macromolecule comprised of Viral Skin Infections of a polysiloxane backbone with covalently bound N-diazeniumdiolate NO donors New Chemical Entity Real-Time NO Released Burst Phase Patients treated to date: >3,400 Time NO NO Time - Sus

  12. Slide 12: Molluscum: No FDA-Approved Treatments

    Molluscum No FDA-Approved Treatments Contagious skin infection caused ~3.4 million ~1.3 million by the molluscipoxvirus, a double- prevalence in the U.S.1 diagnosed per annum1 stranded DNA virus 13 Months ~70% of patients Average time below the age of 10 to resolution Current treatment options are l

  13. Slide 13: Development Pathway Towards Potential Approval

    Development Pathway Towards Potential Approval Potential NDA Filing Targeted 2022 B-SIMPLE1 B-SIMPLE2 B-SIMPLE4 ✓Completed ✓Completed Topline Results Targeted Q2 2021 12 Weeks 12 Weeks 12 Weeks Treatment Treatment Treatment Follow-up Follow-up Follow-up at Week 24 at Week 24 at Week 24 352 Subjects

  14. Slide 14: B-SIMPLE1 and B-SIMPLE2 Integrated Analysis

    B-SIMPLE1 and B-SIMPLE2 Integrated Analysis Demonstrated Statistically Significant (p=0.038) Complete Clearance Rate (27.9%) vs. Vehicle (20.9%) at Week 12 Complete Clearance of All Lesions (ITT1) by Week 12 B-SIMPLE1: 352 Subjects B-SIMPLE2: 355 Subjects p=0.375 p=0.062 35% 35% 30.0% 30% 30% 25.8%

  15. Slide 15: B-SIMPLE4 Pivotal Phase 3 Study Design

    B-SIMPLE4 Pivotal Commenced Study in September 2020 Phase 3 Study Design With Topline Results Targeted Q2 2021 in Molluscum Less than a year away Study Design Based on Learnings Multi-center, double-blind, from B-SIMPLE1 and B-SIMPLE2: randomized, vehicle-controlled study One and two-subject 12 Week

  16. Slide 16: SB206 Commercialization Strategy

    SB206 Commercialization Strategy Preparing for Success Evaluating All Strategic Options Secure Novan Co-Commercialize Commercialization Commercializes with Partner Partner 16

  17. Slide 17: Coronaviridae (COVID-19) Program

    Coronaviridae Nitric oxide may inhibit viral replication by (COVID-19) Program O cytotoxic reactions through intermediates N such as peroxynitrite1 Target Reporting Pre-IND Activities Before Year End Exploring potential of NITRICIL™ as potential topical oral or nasal treatment option for COVID-19 Co

  18. Slide 18: Companion Animal Health Program

    Companion Animal Contracted drug delivery technology Health Program specialist to undertake initial formulation development to assess viability Commenced Exploratory Work to Evaluate NO Engaged third-party animal health experts Application in Adjacent Market to determine technical feasibility and ma

  19. Slide 19: Pipeline Expansion Opportunities

    Pipeline Expansion Opportunities Ongoing In-depth Review for Pipeline Prioritization Product Candidates Indication Pre-IND Phase 1 Phase 2 Phase 3 Program Highlight DERMATOLOGY Two Phase 3’s completed; One confirmatory SB204 Acne Vulgaris Phase 3 needed; Protocol finalized Phase 2 trial complete; Ph

  20. Slide 20: Corporate Overview

    Corporate Overview 20

  21. Slide 21: Financial Profile

    Financial Profile NASDAQ: NOVN Sufficient Capital Through 20211 $35.5M $13.1M $65M 30M Cash as of Proceeds from Market Average June 30, 2020 common stock purchase Cap2 3-month Volume2 agreement in July 2020 Opportunity to Unlock Significant Shareholder Value 21 1: Based on Management’s projections a

  22. Slide 22: Upcoming Targeted Milestones

    Upcoming Targeted Milestones ✓ September 2020: Q1 2021: Complete 2022: Potential NDA SB206 Commenced Study Enrollment Filing with U.S. FDA B-SIMPLE4 ✓ September 2020: Q2 2021: First Patient Dosed Topline Results ✓ September 2020: Ongoing: NITRICIL™ Discovery Selection of NCE for Animal Health Effort

  23. Slide 23: Investment Summary

    Investment Summary Topline Results From Pivotal B-SIMPLE4 Phase 3 Study in Molluscum Targeted Less Than a Year Away Proprietary NITRICIL™ Platform: O N Harnessing the antiviral and Fueling a pipeline with immunomodulatory power of nitric oxide multiple growth opportunities 23

  24. Slide 24: Nitric Oxide-Based Medicine: Investor Relations

    novan.com NASDAQ: NOVN Nitric Oxide-Based Medicine Investor Relations JTC Team 833.475.8247 novn@jtcir.com

Novan — Investor Presentation (September 2020) on 6ix